Background: AAV genomic integration identified in a human case

A 5-year-old boy with severe mucopolysaccharidosis type I (MPS I, Hurler subtype) developed a neuroepithelial tumor four years after intracisternal administration of adeno-associated virus serotype 9 (AAV9) gene therapy. The researchers identified integration of rearranged vector elements into the PLAG1 gene in tumor tissue, along with expression of a chimeric transcript. Published in NEJM, this case report describes the clinical course of one patient and molecular analyses of the tumor.

Recombinant AAV vectors generally do not integrate into the host genome. However, the abstract cites prior studies in neonatal mouse models in which rare genomic integration was associated with tumor development. Against this background, the report examined a tumor and vector integration observed in a human. Findings from prior animal studies and this human case should be interpreted separately.

Key findings: PLAG1 integration and a chimeric transcript

The patient developed a neuroepithelial tumor four years after administration of AAV9 gene therapy into the cisterna magna; the primary tumor was successfully removed by surgery. The provided abstract does not specify the dose, product name, or detailed pathological classification of the tumor.

Molecular analysis of the tumor showed clonal integration of rearranged AAV vector elements within the PLAG1 gene. Expression of a chimeric AAV-PLAG1 transcript joining AAV and PLAG1 sequences was also reported. Thus, both genomic integration of vector elements and expression of an RNA linking the two sequences were identified. The abstract alone does not provide the insertion coordinates, expression level, detailed analytical methods, or functional validation results.

The researchers reported that after surgery the patient continued to have cognitive function above that expected for his age. The authors interpreted this as a finding indicating attenuation of the manifestations of MPS I. The abstract provides neither cognitive test scores nor the duration of postoperative follow-up, so this course cannot be generalized as evidence of treatment efficacy, tumor cure, or freedom from recurrence.

Implications and outlook: A safety signal and the limits of risk estimation

This case is notable for identifying both vector integration and a related transcript in a tumor that developed after intracisternal AAV9 administration. The temporal course of tumor development after treatment, together with molecular observations in the tumor tissue, provides a human case relevant to evaluating the long-term safety of gene therapy.

However, a single-patient report cannot be used to calculate tumor incidence among all treated patients or to conclude that intracisternal administration is riskier than other routes. The findings provide a basis for investigating whether PLAG1 integration and the chimeric transcript may have contributed to tumor formation, but the provided abstract is insufficient to establish the full mechanism of tumor development. Dose-related differences in risk and specific tumorigenic mechanisms also require further data for evaluation.

Safety interpretation should consider not only tumor development and resection outcomes but also the reported cognitive course. Whether this observation occurs in other patients and which conditions it may be associated with remain questions for further research. The key evidence is available in the Europe PMC bibliographic record and abstract for the NEJM paper.